Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Agwu, Allison L ^a   Fairlie, Lee ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Adolescents; Combination antiretroviral therapy; Management; Outcomes 10.7448 ias.16.1.18579; Perinatally HIV infected; Resistance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADOLESCENT DISEASE; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; DISEASE TRANSMISSION; DRUG TREATMENT FAILURE; DRUG UTILIZATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MEDICATION COMPLIANCE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERINATAL MORBIDITY; PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; TRANSITION TO ADULT CARE; TREATMENT OUTCOME; ADOLESCENT; ADOLESCENTS; COMBINATION ANTIRETROVIRAL THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MANAGEMENT; METHODOLOGY; OUTCOMES; PERINATALLY HIV-INFECTED; RESISTANCE;

ADOLESCENTS; COMBINATION ANTIRETROVIRAL THERAPY; MANAGEMENT; OUTCOMES; PERINATALLY HIV-INFECTED; RESISTANCE;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84887291391     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18579     Document Type: Review

References (92)

1. UNAIDS. UNAIDS Report on the global AIDS epidemic 2012; 2012. 1-22-0013.
2. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-44.
3. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach 2010 version. Geneva, Switzerland: World Health Organization; 2010.
4. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med. 2010;61:169-85.
5. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis. 2007;45:918-24.
6. Foster C, Judd A, Tookey P, Tudor-Williams G, Dunn D, Shingadia D, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS. 2009;23:159-66.
7. Centers for Disease Control and Prevention. Pediatric HIV Surveillance (through 2010); 2012. 12-18-0012.
8. Ferrand RA, Munaiwa L, Matsekete J, Bandason T, Nathoo K, Ndhlovu CE, et al. Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe. Clin Infect Dis. 2010;51:844-51.
9. Ferrand RA, Luethy R, Bwakura F, Mujuru H, Miller RF, Corbett EL. HIV infection presenting in older children and adolescents: a case series from Harare, Zimbabwe. Clin Infect Dis. 2007;44:874-8.
10. Dollfus C, Le CJ, Faye A, Blanche S, Briand N, Rouzioux C, et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis. 2010;51:214-24.
11. World Health Organization. Paediatric HIV data and statistics 2010; 2010.
12. Ferrand RA, Desai SR, Hopkins C, Elston CM, Copley SJ, Nathoo K, et al. Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis. 2012;55:145-52.
13. Ferrand RA, Bandason T, Musvaire P, Larke N, Nathoo K, Mujuru H, et al. Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic: a prospective survey. PLoS Med. 2010;7:e1000178.
14. Lowe S, Ferrand RA, Morris-Jones R, Salisbury J, Mangeya N, Dimairo M, et al. Skin disease among human immunodeficiency virus-infected adolescents in Zimbabwe: a strong indicator of underlying HIV infection. Pediatr Infect Dis J. 2010;29:346-51.
15. Harrison A, Pierre RB, Palmer P, Moore J, Davis D, Dunkley-Thompson J, et al. Clinical manifestations of adolescents with HIV/AIDS in Jamaica. West Indian Med J. 2008;57(3):257-64.
16. Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613.
17. Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 3-27-2012. 10-8-2012.
18. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2012. 12-12-2012.
19. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011;30:974-9.
20. Davies MA, Keiser O, Technau K, Eley B, Rabie H, van CG, et al. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:730-7.
21. McNairy ML, Lamb MR, Carter RJ, Fayorsey R, Tene G, Mutabazi V, et al. Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda and Tanzania. J Acquir Immune Defic Syndr. 2012 Oct 29. [Epub ahead of print].
22. Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. 2011;57:165-73.
23. Agwu AL, Korthuis PT, Gaur A, Spector SA, Rutstein R,Warford R, et al. HIV Viremia and advanced immunosuppression among perinatally HIV-infected youth in the multi-site US HIV research network, J Pediatr Infect Dis. 2013 March 12. [Epub ahead of print].
24. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010 revision. Geneva, Switzerland: World Health Organization; 2010.
25. National Department of Health South Africa. Clinical guidelines for the management of HIV & AIDS in adults and adolescents. South Africa; 2010.
26. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwongs M, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 2010;4:515-28.
27. World Health Organization. Technical update of treatment optimization. Use of tenofovir in HIV-infected children and adolescents: a public health perspective. World Health Organization; 2012.
28. Blum RW, McNeely C, Nonnemaker J. Vulnerability, risk, and protection. J Adolesc Health. 2002;31:28-39.
29. Betz CL. Adolescents in transition of adult care: why the concern? Nurs Clin North Am. 2004;39:681-713.
30. Battles HB, Wiener LS. From adolescence through young adulthood: psychosocial adjustment associated with long-term survival of HIV. J Adolesc Health. 2002;30:161-8.
31. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
32. Buchanan AL, Montepiedra G, Sirois PA, Kammerer B, Garvie PA, Storm DS, et al. Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics. 2012;129:e1244-51.
33. Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDS. 2008;22:977-87.
34. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS. 2010;24:97-104.
35. Mellins CA, Tassiopoulos K, Malee K, Moscicki AB, Patton D, Smith R, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDS. 2011;25:413-22.
36. Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:e61.
37. Chandwani S, Koenig LJ, Sill AM, Abramowitz S, Conner LC, D'Angelo L. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health. 2012;51:242-51.
38. Goode M, McMaugh A, Crisp J, Wales S, Ziegler JB. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care. 2003;15:403-8.
39. Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006;118:e1745-57.
40. Kapetanovic S, Wiegand RE, Dominguez K, Blumberg D, Bohannon B, Wheeling J, et al. Associations of medically documented psychiatric diagnoses and risky health behaviors in highly active antiretroviral therapy-experienced perinatally HIV-infected youth. AIDS Patient Care STDS. 2011;25:493-501.
41. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;51:65-71.
42. Bygrave H, Mtangirwa J, Ncube K, Ford N, Kranzer K, Munyaradzi D. Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe. PLoS One. 2012;7:e52856.
43. Williams PL, Van DR, Eagle M, Smith D, Vincent C, Ciupak G, et al. Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study. Am J Epidemiol. 2008;167:1375-86.
44. Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, et al. Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health. 2011;48:637-40.
45. Veinot TC, Flicker SE, Skinner HA, McClelland A, Saulnier P, Read SE, et al. "Supposed to make you better but it doesn't really": HIV-positive youths' perceptions of HIV treatment. J Adolesc Health. 2006;38:261-7.
46. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438.
47. Orban LA, Stein R, Koenig LJ, Conner LC, Rexhouse EL, Lewis JV, et al. Coping strategies of adolescents living with HIV: disease-specific stressors and responses. AIDS Care. 2010;22:420-30.
48. Rosso R, Di BA, Maggiolo F, Nulvesu L, Callegaro AP, Taramasso L, et al. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care. 2012;24:54-8.
49. Wong FL, Hsu AJ, Pham PA, Siberry GK, Hutton N, Agwu AL. Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth. Pediatr Infect Dis J. 2012;31:1279-83.
50. Sawawiboon N, Wittawatmongkol O, Phongsamart W, Prasitsuebsai W, Lapphra K, Chokephaibulkit K. Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine. Int J STD AIDS. 2012;23:497-501.
51. Arrive E, Dicko F, Amghar H, Aka AE, Dior H, Bouah B, et al. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One. 2012;7:e33690.
52. Calabrese SK, Martin S, Wolters PL, Toledo-Tamula MA, Brennan TL, Wood LV. Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents. AIDS Care. 2012;24:1092-6.
53. Mellins CA, Ehrhardt AA. Families affected by pediatric acquired immunodeficiency syndrome: sources of stress and coping. J Dev Behav Pediatr. 1994;15:S54-60.
54. Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, et al. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS. 2008;22:545-52.
55. Reisner S, Mimiaga M, Skeer M, Perkovich B, Johnson C, Safren S. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17(1):14-25.
56. Berry, S, Gebo K, Rutstein R, Warford R, Agwu A. Alive and not well: hospitalization rates highest for oldest perinatally HIV-infected youth 2001-2008. Infect Dis Soc Am. 2011 Oct 20-23. Boston, MA.
57. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46:507-15.
58. Nglazi MD, Kranzer K, Holele P, Kaplan R, Mark D, Jaspan H, et al. Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. BMC Infect Dis. 2012;12:21.
59. Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One. 2011;6:e19261.
60. Kalayjian RC, Spritzler J, Pu M, Landay A, Pollard RB, Stocker V, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. JID. 2005;192.
61. Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, et al. Impact of pre-therapy viral load on virological response to modern first-line HAART. Antivir Ther. 2013 Jan 23. doi: 10.3851/IMP2531. [Epub ahead of print].
62. WHO. WHO HIV Drug Resistance Report 2012. Available from: http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html.
63. Van Zyl GU, Rabie H, Nuttall JJ, Cotton MF. It is time to consider third-line options in antiretroviral-experienced paediatric patients? J Int AIDS Soc. 2011;14(55). doi: 10.1186/1758-2652-14-55.
64. Bangsberg D. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272-8.
65. Gulick R, Ribaudo H, Shikuma C, Lustgarten S, Squires K III, Meyer W, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-61.
66. McIlleron H, Ren Y, Nuttall J, Fairlie L, Rabie H, Cotton M, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011;16(3):417-21.
67. Frohoff C, Moodley M, Fairlie L, Coovadia A, Moultrie H, Kuhn L, et al. Treatment outcomes among HIV-infected infants and young children following modifications to protease inhibitor-based therapy due to tuberculosis treatment. PLoS One. 2011;6(2):e17273
68. Zhao Y, Mu W, Harwell J, Zhou H, Sun X, Cheng Y, et al. Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China. J Acquir Immune Defic Syndr. 2011;58(1):47-53.
69. Wamalwa D, Lehman D, Benki-Nugent S, Gasper M, Gichohi R, Maleche-Obimbo E, et al. Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Nov 28. [Epub ahead of print].
70. Charpentier C, Gody J, Mbitikon O, Moussa S, Matta M, Péré H, et al. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses. 2012;28(1):87-94.
71. Sigaloff K, Calis J, Gleen S, Vugt M, Wit T. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. Lancet Infect Dis. 2011;11(109):769-7.
72. WHO. The global HIV drug resistance surveillance network. Available from: http://www.who.int/drugresistance/hivaids/en/HIVdrugnetwork.pdf.
73. Hogg R, Bangsberg D, Lima V, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3(9): e356.
74. Wang X, Xing H, Ruan Y, Liao L, Zhou H, et al. Effect of viral load and drug resistance on mortality among Chinese HIV-infected patients receiving antiretroviral treatment. J Antivir Antiretrovir. 2012;4:060-5.
75. Agwu A, Bethel J, Hightow-Weidman L, Sleasman J, Wilson C, Rudy B, et al. Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth. AIDS Patient Care STDS. 2012;26(4):193-6.
76. + lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr. 2011;57(3):223-9.
77. Abadi J, Sprecher E, Rosenberg MG, Dobroszycki J, Sansary J, Fennelly G, et al. Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children. J Acquir Immune Defic Syndr. 2006;41(3):298-303.
78. Legrand F, Abadi J, Jordan K, Davenport M, Deeks S, Fennelly G, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS. 2005;19(15):1575-85.
79. Rabie H, Essack G, Cotton M. Monotherapy with lamivudine in HIV-infected children: the experience at Tygerberg hospital. SA HIV Clin Soc Conference. November 25-28, 2012. Capetown, South Africa.
80. Castagna A, Galli L, Bigoloni A, Carini E, Segala D, Antinori A, et al. Impact of lamivudine monotherapy in failing patients with multidrug-resistant HIV: final 48 weeks results (MONO-AIFA FARM7PAZS3). J Int AIDS Soc. 2012;15(6):18289.
81. Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795-803.
82. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-96.
83. Miller T, Borkowsky W, DiMeglio L, Dooley L, Geffner M, Hazra R. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012;13(5):264-75.
84. Deeks S. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-55.
85. Bauermeister JA, Elkington KS, Robbins RN, Kang E, Mellins CA. A prospective study of the onset of sexual behavior and sexual risk in youth perinatally infected with HIV. J Sex Res. 2012;49(5):413-22.
86. Elkington KS, Bauermeister JA, Brackis-Cott E, Dolezal C, Mellins CA. Substance use and sexual risk behaviors in perinatally human immunodeficiency virus-exposed youth: roles of caregivers, peers and HIV status. J Adolesc Health. 2009;45:133-41.
87. Setse RW, Siberry GK, Gravitt PE, Moss WJ, Agwu AL, Wheeling JT, et al. Correlates of sexual activity and sexually transmitted infections among human immunodeficiency virus-infected youth in the LEGACY cohort, United States, 2006. Pediatr Infect Dis J. 2011;30(11):967-73.
88. Tassiopoulos K, Moscicki A, Mellins C, Kacanek D, Malee K, Allison S, et al. Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development. Clin Infect Dis. 2013;56(2):283-90.
89. HIVguidelines.org. Transitioning HIV-infected adolescents into adult care. Available from: http://wwwhivguidelinesorg/clinical-guidelines/ adolescents/transitioning-hiv-infected-adolescents-into-adult-care/.
90. Fair C, Sullivan K, Dizney R, Stackpole A. "It's like losing a part of my family": transition expectations of adolescents living with perinatally acquired HIV and their guardians. AIDS Patient Care STDS. 2012;26(7):423-9.
91. Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas J, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother. 2006;50(11):3548-55.
92. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. Lancet Infect Dis. 2012;12(1):19-26.